Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis

The impact of a 4-week course of therapy with Uralyt-U (potassium-sodium hydrocitrate) on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis. Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week ther...

Full description

Bibliographic Details
Main Authors: M S Eliseyev, I S Denisov, Viktoria Georgiyevna Barskova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2012-03-01
Series:Современная ревматология
Subjects:
Online Access:http://mrj.ima-press.net/index.php/mrj/article/view/400
_version_ 1818570235509211136
author M S Eliseyev
I S Denisov
Viktoria Georgiyevna Barskova
author_facet M S Eliseyev
I S Denisov
Viktoria Georgiyevna Barskova
author_sort M S Eliseyev
collection DOAJ
description The impact of a 4-week course of therapy with Uralyt-U (potassium-sodium hydrocitrate) on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis. Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week therapy with Uralyt-U (p < 0.05), resulting in improvement and normalization of UA metabolism. Uralyt-U therapy is safe and causes no worsening of the parameters of hepatic and renal function and electrolyte exchange.
first_indexed 2024-12-14T06:58:00Z
format Article
id doaj.art-f572a38597fa4e44a9ebfefd365d8a16
institution Directory Open Access Journal
issn 1996-7012
2310-158X
language Russian
last_indexed 2024-12-14T06:58:00Z
publishDate 2012-03-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj.art-f572a38597fa4e44a9ebfefd365d8a162022-12-21T23:12:34ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2012-03-010144481705Clinical experience with Uralyt-U used in patients with gout and nephrolithiasisM S EliseyevI S DenisovViktoria Georgiyevna BarskovaThe impact of a 4-week course of therapy with Uralyt-U (potassium-sodium hydrocitrate) on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis. Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week therapy with Uralyt-U (p < 0.05), resulting in improvement and normalization of UA metabolism. Uralyt-U therapy is safe and causes no worsening of the parameters of hepatic and renal function and electrolyte exchange.http://mrj.ima-press.net/index.php/mrj/article/view/400gouturate nephrolithiasishyperuricemia
spellingShingle M S Eliseyev
I S Denisov
Viktoria Georgiyevna Barskova
Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
Современная ревматология
gout
urate nephrolithiasis
hyperuricemia
title Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_full Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_fullStr Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_full_unstemmed Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_short Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
title_sort clinical experience with uralyt u used in patients with gout and nephrolithiasis
topic gout
urate nephrolithiasis
hyperuricemia
url http://mrj.ima-press.net/index.php/mrj/article/view/400
work_keys_str_mv AT mseliseyev clinicalexperiencewithuralytuusedinpatientswithgoutandnephrolithiasis
AT isdenisov clinicalexperiencewithuralytuusedinpatientswithgoutandnephrolithiasis
AT viktoriageorgiyevnabarskova clinicalexperiencewithuralytuusedinpatientswithgoutandnephrolithiasis